Last reviewed · How we verify

NCT05057455

Effectiveness of the Cytokine Hemadsorption on Sepsis

Completed Last updated 27 September 2021
What this trial tests

trial testing cytokine hemadsorption in Interleukin-6 in 39 participants. Completed in 15 February 2021.

Timeline
1 January 2020
Primary endpoint
30 December 2020
15 February 2021

Quick facts

Lead sponsorBiruni University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment39
Start date1 January 2020
Primary completion30 December 2020
Estimated completion15 February 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Biruni University

Who can join

Adults 18 to 100, any sex, with Interleukin-6. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this prospective study, we aimed to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of cytokine hemadsorption

Trials testing the same drug.

Other Biruni University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05057455.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing